Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
Current Signal: SELL (auto-tracking)
-1.11% $1.780
America/New_York / 17 apr 2024 @ 16:00
FUNDAMENTALS | |
---|---|
MarketCap: | 250.01 mill |
EPS: | -0.450 |
P/E: | -3.96 |
Earnings Date: | Mar 06, 2024 |
SharesOutstanding: | 140.45 mill |
Avg Daily Volume: | 1.944 mill |
RATING 2024-04-17 |
---|
B- |
Sell |
RATINGS | ||
---|---|---|
Rating CashFlow: | Sell | |
Return On Equity: | Strong Buy | |
Return On Asset: | Neutral | |
DE: | Strong Sell | |
P/E: | Sell | |
Price To Book: | Strong Sell |
QUARTER GROWTHS | ||||||
---|---|---|---|---|---|---|
3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
Revenue | ||||||
Gr.Profit | ||||||
Ebit | ||||||
Asset | ||||||
Debt |
PE RATIO: COMPANY / SECTOR |
---|
0.00x |
Company: PE -3.96 | sector: PE -3.05 |
PE RATIO: COMPANY / INDUSTRY |
---|
-0.67x |
Company: PE -3.96 | industry: PE 5.88 |
DISCOUNTED CASH FLOW VALUE |
---|
N/A |
N/A |
Expected Trading Range (DAY) |
---|
$ 1.628 - 1.932 ( +/- 8.54%) |
ATR Model: 14 days |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-03-15 | Sherman Jeffrey W | Buy | 6 502 | Common Stock |
2024-03-15 | Kong Garheng | Buy | 6 474 | Common Stock |
2024-03-15 | Johnson John | Buy | 89 571 | Common Stock |
2024-03-18 | Johnson John | Buy | 215 600 | Common Stock |
2024-03-18 | Johnson John | Sell | 215 600 | Stock Option (Right to Buy) |
INSIDER POWER |
---|
92.75 |
Last 99 transactions |
Buy: 12 203 668 | Sell: 238 056 |
Indicator Signals | |
---|---|
RSI 21 | |
SMA | |
Trend | |
Trend 2 | |
Trend 3 | |
MACD |
Volume Signals | |
---|---|
Price | $1.780 (-1.11% ) |
Volume | 1.497 mill |
Avg. Vol. | 1.944 mill |
% of Avg. Vol | 76.98 % |
Signal 1: | |
Signal 2: |
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
Date | Signal | @ | Closed | % | Feb 8 - 15:35 | sell | $2.70 | N/A | Active |
---|
Xeris Biopharma Holdings, Inc., a biopharmaceutical company, engages in developing and commercializing therapies for patient populations in endocrinology, neurology, and gastroenterology. The company markets Gvoke, a ready-to-use liquid glucagon for the treatment of severe hypoglycemia; and Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome. It also has a pipeline of development programs to extend the marketed products into new indications and uses and bring new products using its proprietary formulation technology platforms, XeriSol and XeriJect. The company was incorporated in 2005 and is headquartered in Chicago, Illinois.